

**Clinical trial results:****A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy****Summary**

EudraCT number	2012-003228-19
Trial protocol	ES DE IT GB PL
Global end of trial date	16 October 2015

Results information

Result version number	v1 (current)
This version publication date	31 October 2016
First version publication date	31 October 2016

Trial information**Trial identification**

Sponsor protocol code	EVP-6124-017
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	IND Number: 076939

Notes:

Sponsors

Sponsor organisation name	Forum Pharmaceuticals, Inc.
Sponsor organisation address	500 Arsenal Street, Watertown, MA, United States, 02472
Public contact	Regulatory Project Manager, INC Research, +44 1276481000, SM_Regaffairs_eu_ap@incresearch.com
Scientific contact	Regulatory Project Manager, INC Research, +44 1276481000, SM_Regaffairs_eu_ap@incresearch.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 May 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	16 October 2015
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To assess the long-term safety of 1 and 2 mg doses of EVP-6124 tablets administered once daily for up to 52 weeks in subjects who received EVP-6124 in both the pivotal and extension studies and up to 26 weeks in subjects who were randomized from placebo to EVP-6124 upon entry into this extension study.

Protection of trial subjects:

There were no specific measures as the only 'invasive' measures were blood sample analyses.

Background therapy:

Patients were enrolled into the antecedent studies (015 and 016) that were stably treated with atypical anti-psychotic agents. These are the standard treatment of choice for this patient population. Only the anti-psychotic clozapine was excluded. This was for two reasons: clozapine treated patients are uniquely 'sicker' as it remains a second or third line treatment choice and clozapine has safety concerns which require special monitoring procedures that would more difficult to incorporate into the studies.

Evidence for comparator: -

Actual start date of recruitment	13 June 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 23
Country: Number of subjects enrolled	Spain: 26
Country: Number of subjects enrolled	United Kingdom: 5
Country: Number of subjects enrolled	Germany: 14
Country: Number of subjects enrolled	Italy: 11
Country: Number of subjects enrolled	Argentina: 37
Country: Number of subjects enrolled	Australia: 2
Country: Number of subjects enrolled	Canada: 26
Country: Number of subjects enrolled	Colombia: 29
Country: Number of subjects enrolled	Mexico: 25
Country: Number of subjects enrolled	Romania: 30
Country: Number of subjects enrolled	Russian Federation: 60
Country: Number of subjects enrolled	Serbia: 7
Country: Number of subjects enrolled	Singapore: 2
Country: Number of subjects enrolled	Ukraine: 127
Country: Number of subjects enrolled	United States: 403

Worldwide total number of subjects	827
EEA total number of subjects	109

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	827
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects who completed double-blind treatment (ie, completion of the Day 182 Visit) in Studies EVP-6124-015 or EVP-6124-016 and who fulfilled all inclusion/exclusion criteria for this extension study were eligible for enrollment.

Pre-assignment period milestones

Number of subjects started	827
Number of subjects completed	827

Period 1

Period 1 title	Overall period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	EVP-6124, 1 mg
------------------	----------------

Arm description:

Subjects who received EVP-6124 during the previous study (EVP-6124-015 or EVP-6124-016) will remain on the same dose. Subjects who received placebo during the pivotal study (EVP-6124-015 or EVP-6124-016) will be randomized (1:1 ratio) to once daily EVP-6124 1 or 2 mg tablets for up to 26 weeks (Days 1-182).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Encenicline
--	-------------

Investigational medicinal product code	EVP-6124
--	----------

Other name	
------------	--

Pharmaceutical forms	Tablet
----------------------	--------

Routes of administration	Oral use
--------------------------	----------

Dosage and administration details:

Throughout the study (Days 1-182), all subjects will be instructed to take 1 tablet of study medication once daily, preferably at the same time (between 8 to 10 AM if feasible) every morning, with an adequate amount of water with or without food (after morning meal is preferred).

Arm title	EVP-6124, 2 mg
------------------	----------------

Arm description:

Subjects who received EVP-6124 during the previous study (EVP-6124-015 or EVP-6124-016) will remain on the same dose. Subjects who received placebo during the pivotal study (EVP-6124-015 or EVP-6124-016) will be randomized (1:1 ratio) to once daily EVP-6124 1 or 2 mg tablets for up to 26 weeks (Days 1-182).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Encenicline
--	-------------

Investigational medicinal product code	EVP-6124
--	----------

Other name	
------------	--

Pharmaceutical forms	Tablet
----------------------	--------

Routes of administration	Oral use
--------------------------	----------

Dosage and administration details:

Throughout the study (Days 1-182), all subjects will be instructed to take 1 tablet of study medication once daily, preferably at the same time (between 8 to 10 AM if feasible) every morning, with an adequate amount of water with or without food (after morning meal is preferred).

Number of subjects in period 1	EVP-6124, 1 mg	EVP-6124, 2 mg
Started	428	399
Completed	248	223
Not completed	180	176
Consent withdrawn by subject	14	12
Physician decision	1	1
Adverse event, non-fatal	13	17
Medication Prohibited by Protocol	2	1
Subject Incarceration	2	1
Substance Abuse	-	1
Sponsor Decision	136	129
Lost to follow-up	9	10
Protocol deviation	3	4

Baseline characteristics

Reporting groups

Reporting group title	EVP-6124, 1 mg
-----------------------	----------------

Reporting group description:

Subjects who received EVP-6124 during the previous study (EVP-6124-015 or EVP-6124-016) will remain on the same dose. Subjects who received placebo during the pivotal study (EVP-6124-015 or EVP-6124-016) will be randomized (1:1 ratio) to once daily EVP-6124 1 or 2 mg tablets for up to 26 weeks (Days 1-182).

Reporting group title	EVP-6124, 2 mg
-----------------------	----------------

Reporting group description:

Subjects who received EVP-6124 during the previous study (EVP-6124-015 or EVP-6124-016) will remain on the same dose. Subjects who received placebo during the pivotal study (EVP-6124-015 or EVP-6124-016) will be randomized (1:1 ratio) to once daily EVP-6124 1 or 2 mg tablets for up to 26 weeks (Days 1-182).

Reporting group values	EVP-6124, 1 mg	EVP-6124, 2 mg	Total
Number of subjects	428	399	827
Age categorical Units: Subjects			
Adults (18-64 years)	428	399	827
Age continuous Units: years			
arithmetic mean	37.4	37	
full range (min-max)	18 to 51	18 to 51	-
Gender categorical Units: Subjects			
Female	151	138	289
Male	277	261	538

End points

End points reporting groups

Reporting group title	EVP-6124, 1 mg
-----------------------	----------------

Reporting group description:

Subjects who received EVP-6124 during the previous study (EVP-6124-015 or EVP-6124-016) will remain on the same dose. Subjects who received placebo during the pivotal study (EVP-6124-015 or EVP-6124-016) will be randomized (1:1 ratio) to once daily EVP-6124 1 or 2 mg tablets for up to 26 weeks (Days 1-182).

Reporting group title	EVP-6124, 2 mg
-----------------------	----------------

Reporting group description:

Subjects who received EVP-6124 during the previous study (EVP-6124-015 or EVP-6124-016) will remain on the same dose. Subjects who received placebo during the pivotal study (EVP-6124-015 or EVP-6124-016) will be randomized (1:1 ratio) to once daily EVP-6124 1 or 2 mg tablets for up to 26 weeks (Days 1-182).

Primary: Treatment emergent adverse events (TEAEs)

End point title	Treatment emergent adverse events (TEAEs) ^[1]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Throughout the study

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: Subjects with any TEAEs	164	149		

Statistical analyses

No statistical analyses for this end point

Primary: Columbia-Suicide Severity Rating Scale (C-SSRS) (Day 182)

End point title	Columbia-Suicide Severity Rating Scale (C-SSRS) (Day 182) ^[2]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

On Days 14, 28, 56, 84, 112, 140, and 182, or ET.

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: Subjects who had any suicidal ideation	4	1		

Statistical analyses

No statistical analyses for this end point

Primary: Calgary Depression Scale for Schizophrenia (CDSS) (change from baseline)

End point title	Calgary Depression Scale for Schizophrenia (CDSS) (change from baseline) ^[3]
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

The CDSS will be completed at Day 182 or ET. The CDSS was performed at the final study visit (Day 182) for the previous study (EVP-6124-015 or EVP-6124-016), and this value will serve as the baseline assessment.

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: n/a				
arithmetic mean (full range (min-max))	-0.1 (-12 to 10)	0 (-9 to 9)		

Statistical analyses

No statistical analyses for this end point

Primary: Simpson-Angus Scale (SAS) (change from baseline)

End point title	Simpson-Angus Scale (SAS) (change from baseline) ^[4]
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

On Days 56, 112, and 182, or ET.

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: n/a				
arithmetic mean (full range (min-max))	0 (-4 to 4)	0 (-4 to 3)		

Statistical analyses

No statistical analyses for this end point

Primary: Heart rate (change from baseline)

End point title | Heart rate (change from baseline)^[5]

End point description:

End point type | Primary

End point timeframe:

On Days 28, 56, 112, and 182, or ET.

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: beats/min				
arithmetic mean (full range (min-max))	2.1 (-42 to 43)	0.4 (-39 to 37)		

Statistical analyses

No statistical analyses for this end point

Primary: QT duration (change from baseline)

End point title | QT duration (change from baseline)^[6]

End point description:

End point type | Primary

End point timeframe:

On Days 28, 56, 112, and 182, or ET.

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: msec				
arithmetic mean (full range (min-max))	-3.5 (-87 to 83)	-1.2 (-82 to 88)		

Statistical analyses

No statistical analyses for this end point

Primary: QTcF - Fridericia's Correction (change from baseline)

End point title | QTcF - Fridericia's Correction (change from baseline)^[7]

End point description:

End point type | Primary

End point timeframe:

On Days 28, 56, 112, and 182, or ET.

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: msec				
arithmetic mean (full range (min-max))	0 (-49 to 50)	-0.8 (-43 to 61)		

Statistical analyses

No statistical analyses for this end point

Primary: QRS Duration (change from baseline)

End point title | QRS Duration (change from baseline)^[8]

End point description:

End point type | Primary

End point timeframe:

On Days 28, 56, 112, and 182, or ET.

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: msec				
arithmetic mean (full range (min-max))	0.1 (-23 to 22)	0.2 (-21 to 19)		

Statistical analyses

No statistical analyses for this end point

Primary: PR Duration (change from baseline)

End point title | PR Duration (change from baseline)^[9]

End point description:

End point type | Primary

End point timeframe:

On Days 28, 56, 112, and 182, or ET.

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: msec				
arithmetic mean (full range (min-max))	-2 (-65 to 73)	0.5 (-26 to 51)		

Statistical analyses

No statistical analyses for this end point

Primary: RR duration (change from baseline)

End point title | RR duration (change from baseline)^[10]

End point description:

End point type | Primary

End point timeframe:

On Days 28, 56, 112, and 182, or ET.

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: msec				
arithmetic mean (full range (min-max))	-22.7 (-472 to 468)	-2 (-567 to 346)		

Statistical analyses

No statistical analyses for this end point

Primary: Basophils (change from baseline)

End point title | Basophils (change from baseline)^[11]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: 10 ⁹ /L				
arithmetic mean (full range (min-max))	0.001 (-0.09 to 0.1)	0 (-0.05 to 0.08)		

Statistical analyses

No statistical analyses for this end point

Primary: Eosinophils (change from baseline)

End point title | Eosinophils (change from baseline)^[12]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: 10 ⁹ /L				
arithmetic mean (full range (min-max))	-0.005 (-0.44 to 0.4)	-0.008 (-0.63 to 0.56)		

Statistical analyses

No statistical analyses for this end point

Primary: Erythrocytes (change from baseline)

End point title | Erythrocytes (change from baseline)^[13]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: 10 ¹² /L				
arithmetic mean (full range (min-max))	-0.009 (-1.03 to 1.79)	0.018 (-1.02 to 2.46)		

Statistical analyses

No statistical analyses for this end point

Primary: Hematocrit (change from baseline)

End point title | Hematocrit (change from baseline)^[14]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: percent				
arithmetic mean (full range (min-max))	0.23 (-7.8 to 15.4)	0.23 (-10.5 to 12.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Hemoglobin (change from baseline)

End point title | Hemoglobin (change from baseline)^[15]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: g/dL				
arithmetic mean (full range (min-max))	0.01 (-3 to 5.2)	0 (-4.1 to 3.2)		

Statistical analyses

No statistical analyses for this end point

Primary: Leukocytes (change from baseline)

End point title | Leukocytes (change from baseline)^[16]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: 10 ⁹ /L				
arithmetic mean (full range (min-max))	0.023 (-5.66 to 6.84)	-0.094 (-5.3 to 5.75)		

Statistical analyses

No statistical analyses for this end point

Primary: Lymphocytes (change from baseline)

End point title | Lymphocytes (change from baseline)^[17]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: 10 ⁹ /L				
arithmetic mean (full range (min-max))	0.027 (-1.5 to 2.1)	0.004 (-1.34 to 2.16)		

Statistical analyses

No statistical analyses for this end point

Primary: Monocytes (change from baseline)

End point title | Monocytes (change from baseline)^[18]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: 10 ⁹ /L				
arithmetic mean (full range (min-max))	-0.021 (-0.78 to 0.66)	-0.018 (-0.6 to 0.41)		

Statistical analyses

No statistical analyses for this end point

Primary: Neutrophils (change from baseline)

End point title | Neutrophils (change from baseline)^[19]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: 10 ⁹ /L				
arithmetic mean (full range (min-max))	0.01 (-6.6 to 6.64)	-0.112 (-4.75 to 4.42)		

Statistical analyses

No statistical analyses for this end point

Primary: Platelets (change from baseline)

End point title | Platelets (change from baseline)^[20]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: 10 ⁹ /L				
arithmetic mean (full range (min-max))	0.6 (-126 to 225)	0.2 (-145 to 162)		

Statistical analyses

No statistical analyses for this end point

Primary: Alanine Aminotransferase (change from baseline)

End point title | Alanine Aminotransferase (change from baseline)^[21]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: IU/L				
arithmetic mean (full range (min-max))	-0.4 (-67 to 112)	1.2 (-87 to 234)		

Statistical analyses

No statistical analyses for this end point

Primary: Albumin (change from baseline)

End point title | Albumin (change from baseline)^[22]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: g/dL				
arithmetic mean (full range (min-max))	-0.03 (-0.9 to 1.1)	-0.05 (-0.9 to 0.7)		

Statistical analyses

No statistical analyses for this end point

Primary: Alkaline Phosphatase (change from baseline)

End point title | Alkaline Phosphatase (change from baseline)^[23]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: IU/L				
arithmetic mean (full range (min-max))	-1 (-51 to 85)	0.5 (-91 to 57)		

Statistical analyses

No statistical analyses for this end point

Primary: Aspartate Aminotransferase (change from baseline)

End point title | Aspartate Aminotransferase (change from baseline)^[24]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: IU/L				
arithmetic mean (full range (min-max))	0.5 (-56 to 217)	1 (-74 to 111)		

Statistical analyses

No statistical analyses for this end point

Primary: Bicarbonate (change from baseline)

End point title | Bicarbonate (change from baseline)^[25]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mEq/L				
arithmetic mean (full range (min-max))	-0.5 (-9 to 8)	-0.5 (-7 to 6)		

Statistical analyses

No statistical analyses for this end point

Primary: Bilirubin (change from baseline)

End point title | Bilirubin (change from baseline)^[26]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[26] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mg/dL				
arithmetic mean (full range (min-max))	0.02 (-0.5 to 2.3)	-0.01 (-1.1 to 1.1)		

Statistical analyses

No statistical analyses for this end point

Primary: Blood Urea Nitrogen (change from baseline)

End point title | Blood Urea Nitrogen (change from baseline)^[27]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mg/dL				
arithmetic mean (full range (min-max))	0 (-8 to 25)	-0.4 (-16 to 9)		

Statistical analyses

No statistical analyses for this end point

Primary: Calcium (change from baseline)

End point title | Calcium (change from baseline)^[28]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mg/dL				
arithmetic mean (full range (min-max))	-0.01 (-1.2 to 1.7)	0.01 (-1.2 to 1.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Chloride (change from baseline)

End point title | Chloride (change from baseline)^[29]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mEq/L				
arithmetic mean (full range (min-max))	-0.2 (-17 to 8)	-0.1 (-10 to 6)		

Statistical analyses

No statistical analyses for this end point

Primary: Creatine Kinase (change from baseline)

End point title | Creatine Kinase (change from baseline)^[30]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: IU/L				
arithmetic mean (full range (min-max))	29.9 (-953 to 4605)	8.9 (-1359 to 4853)		

Statistical analyses

No statistical analyses for this end point

Primary: Creatinine (change from baseline)

End point title | Creatinine (change from baseline)^[31]

End point description:

End point type | Primary

End point timeframe:

Visits 1, 2, 3, 5 and 7

Notes:

[31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mg/dL				
arithmetic mean (full range (min-max))	0.016 (-0.46 to 1.51)	0.003 (-0.47 to 0.39)		

Statistical analyses

No statistical analyses for this end point

Primary: Gamma Glutamyl Transferase (change from baseline)

End point title | Gamma Glutamyl Transferase (change from baseline)^[32]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: IU/L				
arithmetic mean (full range (min-max))	0.1 (-109 to 167)	1.1 (-229 to 78)		

Statistical analyses

No statistical analyses for this end point

Primary: Glomerular Filtration Rate (change from baseline)

End point title	Glomerular Filtration Rate (change from baseline) ^[33]
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mL/min/1.73m ²				
arithmetic mean (full range (min-max))	-0.2 (-32 to 5)	0 (-5 to 5)		

Statistical analyses

No statistical analyses for this end point

Primary: Glucose (change from baseline)

End point title	Glucose (change from baseline) ^[34]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mg/dL				
arithmetic mean (full range (min-max))	-1.3 (-215 to 175)	3.3 (-142 to 208)		

Statistical analyses

No statistical analyses for this end point

Primary: Magnesium (change from baseline)

End point title | Magnesium (change from baseline)^[35]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mg/dL				
arithmetic mean (full range (min-max))	0 (-0.5 to 1)	-0.01 (-0.5 to 0.4)		

Statistical analyses

No statistical analyses for this end point

Primary: Phosphate (change from baseline)

End point title | Phosphate (change from baseline)^[36]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mg/dL				
arithmetic mean (full range (min-max))	-0.02 (-2 to 5.8)	-0.03 (-1.9 to 2.2)		

Statistical analyses

No statistical analyses for this end point

Primary: Potassium (change from baseline)

End point title | Potassium (change from baseline)^[37]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mEq/L				
arithmetic mean (full range (min-max))	0.02 (-1.6 to 1.7)	0.08 (-1.1 to 1.2)		

Statistical analyses

No statistical analyses for this end point

Primary: Prolactin (change from baseline)

End point title | Prolactin (change from baseline)^[38]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[38] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: ug/L				
arithmetic mean (full range (min-max))	1.88 (-149.1 to 175)	-2.25 (-88.9 to 74.8)		

Statistical analyses

No statistical analyses for this end point

Primary: Protein (change from baseline)

End point title | Protein (change from baseline)^[39]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: g/dL				
arithmetic mean (full range (min-max))	-0.05 (-2.1 to 1.2)	-0.04 (-1.7 to 1.1)		

Statistical analyses

No statistical analyses for this end point

Primary: Sodium (change from baseline)

End point title | Sodium (change from baseline)^[40]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[40] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mEq/L				
arithmetic mean (full range (min-max))	0.5 (-7 to 11)	0.6 (-7 to 10)		

Statistical analyses

No statistical analyses for this end point

Primary: Urate (change from baseline)

End point title | Urate (change from baseline)^[41]

End point description:

End point type | Primary

End point timeframe:

These non-fasting laboratory tests will be performed on Days 28, 56, 112, and 182, or ET.

Notes:

[41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mg/dL				
arithmetic mean (full range (min-max))	0.05 (-4.8 to 4.9)	-0.04 (-4.8 to 3)		

Statistical analyses

No statistical analyses for this end point

Primary: Systolic Blood Pressure (change from baseline)

End point title | Systolic Blood Pressure (change from baseline)^[42]

End point description:

End point type | Primary

End point timeframe:

At all study visits (except Day 14 telephone call).

Notes:

[42] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mmHg				
arithmetic mean (full range (min-max))	0.4 (-40 to 41)	0.2 (-31 to 32)		

Statistical analyses

No statistical analyses for this end point

Primary: Diastolic Blood Pressure (change from baseline)

End point title | Diastolic Blood Pressure (change from baseline)^[43]

End point description:

End point type | Primary

End point timeframe:

At all study visits (except Day 14 telephone call).

Notes:

[43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: mmHg				
arithmetic mean (full range (min-max))	0.1 (-32 to 42)	0.7 (-30 to 33)		

Statistical analyses

No statistical analyses for this end point

Primary: Pulse Rate (change from baseline)

End point title | Pulse Rate (change from baseline)^[44]

End point description:

End point type | Primary

End point timeframe:

At all study visits (except Day 14 telephone call).

Notes:

[44] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: beats/min				
arithmetic mean (full range (min-max))	2.3 (-33 to 46)	0.9 (-29 to 27)		

Statistical analyses

No statistical analyses for this end point

Primary: Respiratory Rate (change from baseline)

End point title | Respiratory Rate (change from baseline)^[45]

End point description:

End point type | Primary

End point timeframe:

At all study visits (except Day 14 telephone call).

Notes:

[45] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: breaths/min				
arithmetic mean (full range (min-max))	0.2 (-4 to 12)	-0.2 (-6 to 8)		

Statistical analyses

No statistical analyses for this end point

Primary: Temperature (change from baseline)

End point title | Temperature (change from baseline)^[46]

End point description:

End point type | Primary

End point timeframe:

At all study visits (except Day 14 telephone call).

Notes:

[46] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: celsius temperature				
arithmetic mean (full range (min-max))	0.02 (-1.3 to 1)	0.02 (-1.4 to 1.6)		

Statistical analyses

No statistical analyses for this end point

Primary: Weight (change from baseline)

End point title | Weight (change from baseline)^[47]

End point description:

End point type | Primary

End point timeframe:

At all study visits (except Day 14 telephone call).

Notes:

[47] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This was a safety extension study, so there were no pre-defined statistical analysis.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	428	399		
Units: kilogram(s)				
arithmetic mean (full range (min-max))	-0.45 (-19.9 to 13.5)	-0.04 (-19.1 to 11.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: CGI-S severity scores (change from baseline)

End point title | CGI-S severity scores (change from baseline)

End point description:

End point type | Secondary

End point timeframe:

On Days 56, 112, and 182, or ET.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	421	388		
Units: n/a				
arithmetic mean (full range (min-max))	-0.1 (-2 to 2)	-0.1 (-2 to 3)		

Statistical analyses

No statistical analyses for this end point

Secondary: CGI-C change scores (Day 182)

End point title	CGI-C change scores (Day 182)
End point description:	
End point type	Secondary
End point timeframe:	
On Days 56, 112, and 182, or ET.	

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	421	388		
Units: n/a				
arithmetic mean (full range (min-max))	3.1 (1 to 6)	3.1 (1 to 7)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Concentration of EVP-6124 (Day 182)

End point title	Concentration of EVP-6124 (Day 182)
End point description:	
End point type	Other pre-specified
End point timeframe:	
On Days 28, 56, 112, and 182, or ET.	

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	427	394		
Units: ng/ml				
arithmetic mean (full range (min-max))	1.59224 (0 to 5.06)	3.13547 (0 to 9.45)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Concentration of EVP-6124 N-Oxide Metabolite (Day 182)

End point title	Concentration of EVP-6124 N-Oxide Metabolite (Day 182)
-----------------	--

End point description:

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

On Days 28, 56, 112, and 182, or ET.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	427	394		
Units: ng/ml				
arithmetic mean (full range (min-max))	0.17276 (0 to 0.778)	0.30632 (0 to 1.05)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Concentration of EVP-6124 Acid Metabolite (Day 182)

End point title	Concentration of EVP-6124 Acid Metabolite (Day 182)
-----------------	---

End point description:

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

On Days 28, 56, 112, and 182, or ET.

End point values	EVP-6124, 1 mg	EVP-6124, 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	427	394		
Units: ng/ml				
arithmetic mean (full range (min-max))	0.22055 (0 to 0.678)	0.44114 (0 to 2.24)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Throughout the study

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

Reporting groups

Reporting group title	EVP-6124, 1 mg
-----------------------	----------------

Reporting group description:

Subjects who received EVP-6124 during the previous study (EVP-6124-015 or EVP-6124-016) will remain on the same dose. Subjects who received placebo during the pivotal study (EVP-6124-015 or EVP-6124-016) will be randomized (1:1 ratio) to once daily EVP-6124 1 or 2 mg tablets for up to 26 weeks (Days 1-182).

Reporting group title	EVP-6124, 2 mg
-----------------------	----------------

Reporting group description:

Subjects who received EVP-6124 during the previous study (EVP-6124-015 or EVP-6124-016) will remain on the same dose. Subjects who received placebo during the pivotal study (EVP-6124-015 or EVP-6124-016) will be randomized (1:1 ratio) to once daily EVP-6124 1 or 2 mg tablets for up to 26 weeks (Days 1-182).

Serious adverse events	EVP-6124, 1 mg	EVP-6124, 2 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 428 (2.80%)	20 / 399 (5.01%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Burns third degree			

subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			
Homicide			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	

Volvulus			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Psychiatric decompensation			
subjects affected / exposed	7 / 428 (1.64%)	7 / 399 (1.75%)	
occurrences causally related to treatment / all	0 / 12	1 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paranoia			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Substance abuse			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal behaviour			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	

Bronchitis			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	EVP-6124, 1 mg	EVP-6124, 2 mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	164 / 428 (38.32%)	149 / 399 (37.34%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 428 (0.47%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Hyperaemia			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 428 (0.47%)	2 / 399 (0.50%)	
occurrences (all)	164	149	
Fatigue			
subjects affected / exposed	2 / 428 (0.47%)	2 / 399 (0.50%)	
occurrences (all)	164	149	
Chest pain			
subjects affected / exposed	1 / 428 (0.23%)	1 / 399 (0.25%)	
occurrences (all)	164	149	

Non-cardiac chest pain			
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)	
occurrences (all)	164	149	
Drug withdrawal syndrome			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Feeling jittery			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Hernia			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Inflammation			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Injection site swelling			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Malaise			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Oedema peripheral			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Pain			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Peripheral swelling			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Immune system disorders			
Sarcoidosis			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Seasonal allergy			

subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Social circumstances Homicide subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	2 / 428 (0.47%) 164	1 / 399 (0.25%) 149	
Amenorrhoea subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Menstrual disorder subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	4 / 428 (0.93%) 164	1 / 399 (0.25%) 149	
Rhinorrhoea subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	2 / 399 (0.50%) 149	
Nasal congestion subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	1 / 399 (0.25%) 149	
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	1 / 399 (0.25%) 149	
Allergic pharyngitis subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Asthma			

subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Dyspnoea		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Epistaxis		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Nasal polyps		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Nocturnal dyspnoea		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Oropharyngeal discomfort		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Productive cough		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Respiratory disorder		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Respiratory distress		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Rhinitis allergic		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Sneezing		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Psychiatric disorders		
Insomnia		
subjects affected / exposed	14 / 428 (3.27%)	8 / 399 (2.01%)
occurrences (all)	164	149

Psychiatric decompensation subjects affected / exposed occurrences (all)	8 / 428 (1.87%) 164	14 / 399 (3.51%) 149
Anxiety subjects affected / exposed occurrences (all)	10 / 428 (2.34%) 164	5 / 399 (1.25%) 149
Depression subjects affected / exposed occurrences (all)	5 / 428 (1.17%) 164	0 / 399 (0.00%) 149
Psychotic disorder subjects affected / exposed occurrences (all)	3 / 428 (0.70%) 164	2 / 399 (0.50%) 149
Suicidal ideation subjects affected / exposed occurrences (all)	3 / 428 (0.70%) 164	2 / 399 (0.50%) 149
Irritability subjects affected / exposed occurrences (all)	2 / 428 (0.47%) 164	2 / 399 (0.50%) 149
Panic attack subjects affected / exposed occurrences (all)	3 / 428 (0.70%) 164	1 / 399 (0.25%) 149
Initial insomnia subjects affected / exposed occurrences (all)	2 / 428 (0.47%) 164	1 / 399 (0.25%) 149
Agitation subjects affected / exposed occurrences (all)	2 / 428 (0.47%) 164	0 / 399 (0.00%) 149
Delusion subjects affected / exposed occurrences (all)	2 / 428 (0.47%) 164	0 / 399 (0.00%) 149
Depressed mood subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	1 / 399 (0.25%) 149
Restlessness subjects affected / exposed occurrences (all)	2 / 428 (0.47%) 164	0 / 399 (0.00%) 149

Abnormal dreams		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Affect lability		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Aggression		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Bruxism		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Hallucination		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Hallucination, auditory		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Hallucination, visual		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Homicidal ideation		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Middle insomnia		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Paranoia		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Sleep disorder		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Sleep terror		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149

Stress			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Substance abuse			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Suicidal behaviour			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Tension			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Investigations			
Weight increased			
subjects affected / exposed	10 / 428 (2.34%)	7 / 399 (1.75%)	
occurrences (all)	164	149	
Weight decreased			
subjects affected / exposed	4 / 428 (0.93%)	6 / 399 (1.50%)	
occurrences (all)	164	149	
Blood creatine phosphokinase increased			
subjects affected / exposed	5 / 428 (1.17%)	4 / 399 (1.00%)	
occurrences (all)	164	149	
Alanine aminotransferase increased			
subjects affected / exposed	4 / 428 (0.93%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Blood glucose increased			
subjects affected / exposed	1 / 428 (0.23%)	4 / 399 (1.00%)	
occurrences (all)	164	149	
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 428 (0.47%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 428 (0.23%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Urine leukocyte esterase positive			

subjects affected / exposed occurrences (all)	2 / 428 (0.47%) 164	0 / 399 (0.00%) 149	
White blood cell count increased subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	1 / 399 (0.25%) 149	
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Blood potassium decreased subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Blood pressure increased subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Electrocardiogram ST segment depression subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Electrocardiogram T wave abnormal subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Neutrophil count increased subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
White blood cells urine positive subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	2 / 428 (0.47%) 164	2 / 399 (0.50%) 149	
Laceration			

subjects affected / exposed	1 / 428 (0.23%)	2 / 399 (0.50%)
occurrences (all)	164	149
Sunburn		
subjects affected / exposed	3 / 428 (0.70%)	0 / 399 (0.00%)
occurrences (all)	164	149
Fall		
subjects affected / exposed	2 / 428 (0.47%)	0 / 399 (0.00%)
occurrences (all)	164	149
Multiple injuries		
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)
occurrences (all)	164	149
Road traffic accident		
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)
occurrences (all)	164	149
Skin abrasion		
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)
occurrences (all)	164	149
Wound		
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)
occurrences (all)	164	149
Arthropod bite		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Burns first degree		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Burns third degree		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Excoriation		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Intentional overdose		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Joint dislocation		

subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Ligament injury subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Ligament sprain subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Meniscus injury subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Nail injury subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Spinal fracture subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Toxicity to various agents subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Upper limb fracture subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Periorbital contusion subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Cardiac disorders			
Atrioventricular block first degree subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Tachycardia subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Nervous system disorders Headache			

subjects affected / exposed	24 / 428 (5.61%)	12 / 399 (3.01%)
occurrences (all)	164	149
Dizziness		
subjects affected / exposed	6 / 428 (1.40%)	4 / 399 (1.00%)
occurrences (all)	164	149
Tremor		
subjects affected / exposed	2 / 428 (0.47%)	4 / 399 (1.00%)
occurrences (all)	164	149
Somnolence		
subjects affected / exposed	3 / 428 (0.70%)	1 / 399 (0.25%)
occurrences (all)	164	149
Paraesthesia		
subjects affected / exposed	2 / 428 (0.47%)	1 / 399 (0.25%)
occurrences (all)	164	149
Akathisia		
subjects affected / exposed	1 / 428 (0.23%)	1 / 399 (0.25%)
occurrences (all)	164	149
Memory impairment		
subjects affected / exposed	2 / 428 (0.47%)	0 / 399 (0.00%)
occurrences (all)	164	149
Mental impairment		
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)
occurrences (all)	164	149
Bradykinesia		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Carpal tunnel syndrome		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Disturbance in attention		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Hypersomnia		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Hypoaesthesia		

subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Intercostal neuralgia subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Lethargy subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Restless legs syndrome subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Tension headache subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Blood and lymphatic system disorders			
Neutropenia subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	1 / 399 (0.25%) 149	
Iron deficiency anaemia subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Leukopenia subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Vertigo subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	2 / 399 (0.50%) 149	
Dry eye			

subjects affected / exposed	1 / 428 (0.23%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Iritis			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Oculogyric crisis			
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Scleral hyperaemia			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Vitreous floaters			
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	11 / 428 (2.57%)	14 / 399 (3.51%)	
occurrences (all)	164	149	
Diarrhoea			
subjects affected / exposed	6 / 428 (1.40%)	9 / 399 (2.26%)	
occurrences (all)	164	149	
Nausea			
subjects affected / exposed	8 / 428 (1.87%)	3 / 399 (0.75%)	
occurrences (all)	164	149	
Toothache			
subjects affected / exposed	4 / 428 (0.93%)	4 / 399 (1.00%)	
occurrences (all)	164	149	
Abdominal pain upper			
subjects affected / exposed	5 / 428 (1.17%)	1 / 399 (0.25%)	
occurrences (all)	164	149	
Dyspepsia			
subjects affected / exposed	2 / 428 (0.47%)	4 / 399 (1.00%)	
occurrences (all)	164	149	
Abdominal pain			
subjects affected / exposed	1 / 428 (0.23%)	3 / 399 (0.75%)	
occurrences (all)	164	149	

Vomiting		
subjects affected / exposed	3 / 428 (0.70%)	1 / 399 (0.25%)
occurrences (all)	164	149
Dry mouth		
subjects affected / exposed	2 / 428 (0.47%)	1 / 399 (0.25%)
occurrences (all)	164	149
Food poisoning		
subjects affected / exposed	1 / 428 (0.23%)	1 / 399 (0.25%)
occurrences (all)	164	149
Abdominal hernia		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Dental caries		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Dysphagia		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Faeces hard		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Faeces soft		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Haemorrhoids		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Large intestine polyp		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Lip blister		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Lip pain		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149

Salivary hypersecretion subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Tooth impacted subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Volvulus subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Skin and subcutaneous tissue disorders			
Acne subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Alopecia subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Eczema subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Hyperhidrosis subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Rash subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Rash papular subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Skin exfoliation subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Swelling face subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Urticaria			

subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Renal and urinary disorders			
Hypertonic bladder subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	1 / 399 (0.25%) 149	
Pollakiuria subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	1 / 399 (0.25%) 149	
Bladder disorder subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Cystitis haemorrhagic subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Enuresis subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Haematuria subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Urine flow decreased subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Endocrine disorders			
Hyperprolactinaemia subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	2 / 399 (0.50%) 149	
Goitre subjects affected / exposed occurrences (all)	0 / 428 (0.00%) 164	1 / 399 (0.25%) 149	
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 428 (0.23%) 164	0 / 399 (0.00%) 149	
Musculoskeletal and connective tissue disorders			

Back pain		
subjects affected / exposed	2 / 428 (0.47%)	6 / 399 (1.50%)
occurrences (all)	164	149
Arthralgia		
subjects affected / exposed	2 / 428 (0.47%)	2 / 399 (0.50%)
occurrences (all)	164	149
Muscle spasms		
subjects affected / exposed	2 / 428 (0.47%)	1 / 399 (0.25%)
occurrences (all)	164	149
Pain in extremity		
subjects affected / exposed	1 / 428 (0.23%)	2 / 399 (0.50%)
occurrences (all)	164	149
Arthritis		
subjects affected / exposed	2 / 428 (0.47%)	0 / 399 (0.00%)
occurrences (all)	164	149
Myalgia		
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)
occurrences (all)	164	149
Temporomandibular joint syndrome		
subjects affected / exposed	1 / 428 (0.23%)	1 / 399 (0.25%)
occurrences (all)	164	149
Coccydynia		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Muscle rigidity		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Musculoskeletal chest pain		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Musculoskeletal pain		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Periarthritis		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149

Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	13 / 428 (3.04%)	20 / 399 (5.01%)	
occurrences (all)	164	149	
Influenza			
subjects affected / exposed	3 / 428 (0.70%)	7 / 399 (1.75%)	
occurrences (all)	164	149	
Upper respiratory tract infection			
subjects affected / exposed	8 / 428 (1.87%)	2 / 399 (0.50%)	
occurrences (all)	164	149	
Urinary tract infection			
subjects affected / exposed	7 / 428 (1.64%)	3 / 399 (0.75%)	
occurrences (all)	164	149	
Bronchitis			
subjects affected / exposed	4 / 428 (0.93%)	2 / 399 (0.50%)	
occurrences (all)	164	149	
Ear infection			
subjects affected / exposed	2 / 428 (0.47%)	3 / 399 (0.75%)	
occurrences (all)	164	149	
Pharyngitis			
subjects affected / exposed	2 / 428 (0.47%)	2 / 399 (0.50%)	
occurrences (all)	164	149	
Gastroenteritis			
subjects affected / exposed	1 / 428 (0.23%)	2 / 399 (0.50%)	
occurrences (all)	164	149	
Abscess limb			
subjects affected / exposed	2 / 428 (0.47%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Cellulitis			
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)	
occurrences (all)	164	149	
Gastroenteritis viral			
subjects affected / exposed	2 / 428 (0.47%)	0 / 399 (0.00%)	
occurrences (all)	164	149	
Pneumonia			

subjects affected / exposed	2 / 428 (0.47%)	0 / 399 (0.00%)
occurrences (all)	164	149
Respiratory tract infection		
subjects affected / exposed	1 / 428 (0.23%)	1 / 399 (0.25%)
occurrences (all)	164	149
Sinusitis		
subjects affected / exposed	1 / 428 (0.23%)	1 / 399 (0.25%)
occurrences (all)	164	149
Viral upper respiratory tract infection		
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)
occurrences (all)	164	149
Appendicitis		
subjects affected / exposed	0 / 428 (0.00%)	2 / 399 (0.50%)
occurrences (all)	164	149
Conjunctivitis		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Diverticulitis		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Folliculitis		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Furuncle		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Gingivitis		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Helicobacter gastritis		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Hordeolum		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Infected bites		

subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Laryngitis		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Otitis externa		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Otitis media		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Pharyngitis streptococcal		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Respiratory tract infection viral		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Skin candida		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Subcutaneous abscess		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Tonsillitis		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Tooth abscess		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Tooth infection		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149
Varicella		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Metabolism and nutrition disorders		

Hyperglycaemia		
subjects affected / exposed	2 / 428 (0.47%)	1 / 399 (0.25%)
occurrences (all)	164	149
Increased appetite		
subjects affected / exposed	1 / 428 (0.23%)	2 / 399 (0.50%)
occurrences (all)	164	149
Vitamin D deficiency		
subjects affected / exposed	1 / 428 (0.23%)	1 / 399 (0.25%)
occurrences (all)	164	149
Decreased appetite		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Food craving		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Gout		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Hypercholesterolaemia		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Hyperlipidaemia		
subjects affected / exposed	1 / 428 (0.23%)	0 / 399 (0.00%)
occurrences (all)	164	149
Type 2 diabetes mellitus		
subjects affected / exposed	0 / 428 (0.00%)	1 / 399 (0.25%)
occurrences (all)	164	149

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 March 2013	Protocol Amendment 1 (08 March 2013)
02 August 2013	Protocol Amendment 2 (02 August 2013)
26 August 2014	Protocol Amendment 2.1 (26 August 2014)

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported